Hung G-Y, Chiou T-J, Hsieh Y-L, Chen P-M, Hwang B
Department of Pediatrics, Taipei Veterans General Hospital, Tapei, Taiwan, ROC.
Bone Marrow Transplant. 2002 Jan;29(1):67-70. doi: 10.1038/sj.bmt.1703316.
We report a nonmyeloablative allogeneic bone marrow transplant (allo-BMT) from an HLA-matched unrelated donor in a case of acute myeloid leukemia (AML), M2 with t(8;21)(q22;q22) and the presence of orbital granulocytic sarcoma (GS), who had residual tumor after conventional chemotherapy. The course of BMT was well tolerated, with no major procedure-related toxicity. The residual orbital GS regressed completely 4 months after BMT. She is currently 19 months post BMT, disease-free. To our knowledge, this is the first reported pediatric patient with AML, GS and t(8;21)(q22;q22) who received a nonmyeloablative allo-BMT.
我们报告了1例急性髓系白血病（AML）M2型伴t(8;21)(q22;q22)且存在眼眶粒细胞肉瘤（GS）的患者，在接受传统化疗后仍有残留肿瘤，接受了来自人类白细胞抗原（HLA）匹配的无关供者的非清髓性异基因骨髓移植（allo-BMT）。BMT过程耐受性良好，无主要的与手术相关的毒性反应。BMT后4个月，残留的眼眶GS完全消退。她目前处于BMT后19个月，无病生存。据我们所知，这是首例报道的接受非清髓性allo-BMT的患有AML、GS和t(8;21)(q22;q22)的儿科患者。
Zotero 插件